It is also estimated that more than 8.5 million adults, including the elderly over age 65 years, are infected and 900,000 patients are hospitalized annually due to RSV infection in the United States and major European countries. In the United States alone there are 177,500 hospitalizations among high risk adults resulting in annual medical costs exceeding $1 billion. There is currently no approved vaccine for the prevention of RSV; the market potential for such a vaccine would be well in excess of $1 billion annually.
About the University of Massachusetts Medical School
The University of Massachusetts Medical School is one of the fastest growing academic health centers in the country and has built a reputation as a world-class research institution, consistently producing noteworthy advances in clinical and basic research. The Medical School attracts more than $255 million in extramural research funding annually. Research dollars enable UMMS scientists to explore human
|SOURCE Novavax, Inc.|
Copyright©2010 PR Newswire.
All rights reserved